ChEMBL ligand: CHEMBL8 (BAY O 9867 FREE BASE, BAY-O-9867 FREE BASE, BAY Q 3939, BAY-Q-3939, BAYQ3939, Cetraxal, Ciloxan, Cipro, Ciprobay, Ciprofloxacin, Ciprofloxacine, Ciprofloxacino, Ciprofloxacinum, NSC-758467, Otiprio, Velmonit)
CYP3A4/Cytochrome P450 3A4 in Human [ChEMBL: CHEMBL340] [GtoPdb: 1337] [UniProtKB: P08684] There should be some charts here, you may need to enable JavaScript!
DNA gyrase subunit A/DNA gyrase subunit B/DNA gyrase in Escherichia coli [ChEMBL: CHEMBL2094139] [GtoPdb: 3217, 3218] [UniProtKB: P0AES4, P0AES6] DNA gyrase in S.aureus [ChEMBL: CHEMBL3038482] [UniProtKB: P0A0K8, P20831] There should be some charts here, you may need to enable JavaScript!
DNA gyrase subunit A in Escherichia coli [ChEMBL: CHEMBL1858] [GtoPdb: 3217] [UniProtKB: P0AES4] There should be some charts here, you may need to enable JavaScript!
DNA gyrase subunit A/DNA gyrase subunit B in Mycobacterium tuberculosis [ChEMBL: CHEMBL3430898] [UniProtKB: P9WG45, P9WG47] There should be some charts here, you may need to enable JavaScript!
DNA gyrase subunit B in S.aureus [ChEMBL: CHEMBL1921666] [UniProtKB: P0A0K8] There should be some charts here, you may need to enable JavaScript!
DNA topoisomerase 4 subunit B in S.aureus [ChEMBL: CHEMBL2150841] [UniProtKB: P0C1S7] There should be some charts here, you may need to enable JavaScript!
DNA topoisomerase II alpha in Human [ChEMBL: CHEMBL1806] [GtoPdb: 2637] [UniProtKB: P11388] There should be some charts here, you may need to enable JavaScript!
GABAA receptor π subunit/GABAA receptor β1 subunit/GABAA receptor δ subunit/GABAA receptor γ2 subunit/GABAA receptor α5 subunit/GABAA receptor α3 subunit/GABAA receptor γ1 subunit/GABAA receptor α2 subunit/GABAA receptor α4 subunit/GABAA receptor γ3 subunit/GABAA receptor α6 subunit/GABAA receptor α1 subunit/GABAA receptor β3 subunit/GABAA receptor β2 subunit/GABAA receptor ε subunit/GABA-A receptor; anion channel in Rat [ChEMBL: CHEMBL1907607] [GtoPdb: 419, 410, 416, 414, 408, 406, 413, 405, 407, 415, 409, 404, 412, 411, 417] [UniProtKB: O09028, P15431, P18506, P18508, P19969, P20236, P23574, P23576, P28471, P28473, P30191, P62813, P63079, P63138, Q91ZM7, Q9ES14] There should be some charts here, you may need to enable JavaScript!
Kv11.1/HERG in Human [ChEMBL: CHEMBL240] [GtoPdb: 572] [UniProtKB: Q12809] There should be some charts here, you may need to enable JavaScript!
H3 receptor/Histamine H3 receptor in Rat [ChEMBL: CHEMBL4124] [GtoPdb: 264] [UniProtKB: Q9QYN8] There should be some charts here, you may need to enable JavaScript!
Human immunodeficiency virus type 1 integrase in Human immunodeficiency virus 1 [ChEMBL: CHEMBL3471] [UniProtKB: Q7ZJM1] There should be some charts here, you may need to enable JavaScript!
Multidrug resistance protein mdtK in Escherichia coli [ChEMBL: CHEMBL1681613] [UniProtKB: P37340] There should be some charts here, you may need to enable JavaScript!
Plasmodium berghei [ChEMBL: CHEMBL612653] There should be some charts here, you may need to enable JavaScript!
Plasmodium falciparum [ChEMBL: CHEMBL364] There should be some charts here, you may need to enable JavaScript!
Topoisomerase IV in S.aureus [ChEMBL: CHEMBL3038508] [UniProtKB: P0C1S7, P0C1U9] There should be some charts here, you may need to enable JavaScript!
Topoisomerase IV subunit A in S.aureus [ChEMBL: CHEMBL4088] [UniProtKB: P0C1U9] DNA topoisomerase 4 subunit A/Topoisomerase IV subunit A in Escherichia coli [ChEMBL: CHEMBL1895] [GtoPdb: 3225] [UniProtKB: P0AFI2] There should be some charts here, you may need to enable JavaScript!

DB	Assay description	Assay Type	Standard value	Standard parameter	Original value	Original units	Original parameter	Reference
CYP3A4/Cytochrome P450 3A4 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL340] [GtoPdb: 1337] [UniProtKB: P08684]
ChEMBL	null: A commercially available P450-GLO Assay kit (Promega Corporation, Madison Wis.) is used to screen various compounds for CYP3A4A inhibition activity. CYP3A4A is thought to be one of the primary CYP isoforms responsible for retinoic acid metabolism in the skin. Three benchmark agents, liarozole, climbazole, and ketoconazole, were assessed for CYP3A4 inhibition to confirm that the inhibition activity (the IC50 for CYP3A4 inhibition) measured by the assay corresponds to the activity reported by the published literature. The results show that the substituted azole compounds having the specific structure set forth herein are CYP inhibitors, and thus function as RAMBAs.	B	5	pIC50	>10000	nM	IC50	US-9138393-B2. Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin (2015)
ChEMBL	In vitro CYP3A4 Inhibition Assay: Cytochrome P450 is a large and diverse group of enzymes that catalyze the oxidation of organic substances. Some members of the CYP family contribute to the elimination of ATRA by catalyzing its 4-hydroxylation in the mammalian liver and skin, including that of humans as well as swine. Applicant evaluated the potential RAMBA activity of several azoles using pig liver microsomes, a rich source of CYP activity, comprising many different CYP 450 isoforms. Therefore, this approach, while a reasonable way to assess CYP inhibitors with broad activities may or may not be the best way to discover RAMBAs with selectivity for the skin, which has a much more narrow complement of CYP expression. As understanding in this area has progressed, a more specific CYP inhibition assay can be used to provide better predictivity of activity in human skin. Nevertheless, this assay may still be used as a general predictor of overall CYP activity.	B	5	pIC50	>10000	nM	IC50	US-9144538-B2. Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin (2015)
DNA gyrase subunit A/DNA gyrase subunit B/DNA gyrase in Escherichia coli (target type: PROTEIN COMPLEX) [ChEMBL: CHEMBL2094139] [GtoPdb: 3217, 3218] [UniProtKB: P0AES4, P0AES6]
ChEMBL	Inhibition of Escherichia coli DNA gyrase assessed as reduction in enzyme-mediated DNA supercoiling using relaxed pBR322 substrate incubated for 60 mins by electrophoresis method	B	5.28	pIC50	5230	nM	IC50	Bioorg Med Chem (2014) 22: 3620-3628 [PMID:24882676]
ChEMBL	Inhibition of Escherichia coli DNA gyrase supercoiling activity using pBR322 as substrate incubated for 30 mins by fluorimetric assay	B	6.08	pIC50	830	nM	IC50	Eur J Med Chem (2022) 228: 114021-114021 [PMID:34871841]
ChEMBL	Inhibition of Escherichia coli DNA gyrase supercoiling activity using topoisomerase II treated decatenated kDNA as substrate incubated for 15 to 30 mins by agarose gel electrophoresis analysis	B	6.18	pIC50	661	nM	IC50	Bioorg Med Chem (2022) 73: 117004-117004 [PMID:36148773]
ChEMBL	Inhibition of Escherichia coli DNA gyrase supercoiling activity using pBR322 as substrate incubated for 30 mins measured by gel-based assay	B	6.22	pIC50	600	nM	IC50	RSC Med Chem (2022) 13: 831-839 [PMID:35919336]
ChEMBL	Inhibition of Escherichia coli JMtacA/JMtacB DNA gyrase subunit A2B2 S83W mutant using relaxed pBR322 DNA as substrate incubated for 30 mins in presence of ATP by ethidium bromide staining based agarose gel electrophoresis	B	6.3	pIC50	500	nM	IC50	Medchemcomm (2016) 7: 1387-1391
ChEMBL	Inhibitory activity against DNA gyrase enzyme was determined by supercoiling assay with Escherichia coli DNA gyrase	B	6.3	pIC50	500	nM	IC50	Bioorg Med Chem Lett (2003) 13: 4229-4233 [PMID:14623007]
ChEMBL	Inhibition of recombinant full-length C-terminal His6-tagged Escherichia coli DNA gyrase AB supercoiling activity using relaxed DNA as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by size exclusion HPLC analysis	B	6.31	pIC50	490	nM	IC50	J Med Chem (2020) 63: 7773-7816 [PMID:32634310]
ChEMBL	Inhibition of Escherichia coli DNA gyrase using relaxed DNA as substrate incubated for 15 mins by ethidium bromide-based agarose gel electrophoresis	B	6.36	pIC50	440	nM	IC50	Eur J Med Chem (2020) 193: 112222-112222 [PMID:32200200]
ChEMBL	Inhibition of Escherichia coli DNA gyrase A2B2 using relaxed pNO1 as substrate	B	6.51	pIC50	310	nM	IC50	J Med Chem (2018) 61: 3565-3581 [PMID:29596745]
ChEMBL	Inhibition of reconstituted Escherichia coli DNA gyrase subunit AB assessed as reduction of DNA supercoiling activity using pBR322 DNA substrate	B	6.52	pIC50	300	nM	IC50	Antimicrob Agents Chemother (2008) 52: 1382-1390 [PMID:18268084]
ChEMBL	Inhibition of DNA gyrase supercoiling in Escherichia coli ATCC 25922	B	6.52	pIC50	300	nM	IC50	J Med Chem (2006) 49: 39-42 [PMID:16392790]
ChEMBL	Inhibitory activity against wild type Escherichia coli gyrase	B	6.52	pIC50	300	nM	IC50	Bioorg Med Chem Lett (2006) 16: 1272-1276 [PMID:16337791]
ChEMBL	Inhibition of Escherichia coli DNA gyrase (A2B2 tetramer) using relaxed pBR322 as substrate preincubated for 30 mins followed by enzyme addition by SYBR staining-based agarose gel electrophoresis method	B	6.55	pIC50	280	nM	IC50	Bioorg Med Chem (2019) 27: 114962-114962 [PMID:31307763]
ChEMBL	Inhibition of Escherichia coli DNA gyrase using fluorescence-tagged DNA by fluorescenct polarization assay	B	6.57	pIC50	270	nM	IC50	J Med Chem (2014) 57: 9078-9095 [PMID:25286019]
ChEMBL	Inhibition of Escherichia coli DNA gyrase by fluorescence based microtiter plate reader assay	B	6.64	pIC50	230	nM	IC50	Bioorg Med Chem Lett (2022) 57: 128499-128499 [PMID:34906671]
ChEMBL	Inhibition of Escherichia coli DNA gyrase assessed as supercoiled plasmid DNA formation after 30 mins by electrophoretic analysis	B	6.7	pIC50	200	nM	IC50	J Med Chem (2014) 57: 8398-8420 [PMID:25238443]
ChEMBL	Inhibition of Escherichia coli DNA gyrase using relaxed PBR322 plasmid DNA as substrate incubated for 30 mins by ethidium bromide staining based agarose gel electrophoresis method	B	6.7	pIC50	200	nM	IC50	J Med Chem (2020) 63: 11707-11724 [PMID:32924479]
ChEMBL	Inhibition of Escherichia coli gyrase	F	6.7	pIC50	200	nM	IC50	J Med Chem (2006) 49: 6435-6438 [PMID:17064062]
ChEMBL	Inhibition of Escherichia coli DNA gyrase assessed as inhibition of pUC19 supercoiling after 30 mins by agarose gel electrophoresis	B	6.77	pIC50	170	nM	IC50	Medchemcomm (2017) 8: 942-951 [PMID:30034678]
ChEMBL	Inhibition of Escherichia coli DNA gyrase after 1 hr by agarose gel electrophoresis	B	6.82	pIC50	150	nM	IC50	Eur J Med Chem (2015) 97: 94-103 [PMID:25951434]
ChEMBL	Inhibition of Escherichia coli DNA gyrase super-coiling activity using relaxed pNO1 DNA as substrate incubated for 30 mins by fluorescence assay	B	6.91	pIC50	122	nM	IC50	Eur J Med Chem (2019) 179: 576-590 [PMID:31279292]
ChEMBL	Inhibition of Escherichia coli DNA gyrase supercoiling activity	B	7.35	pIC50	45	nM	IC50	Bioorg Med Chem Lett (2022) 65: 128648-128648 [PMID:35231579]
DNA gyrase in S.aureus (target type: PROTEIN COMPLEX) [ChEMBL: CHEMBL3038482] [UniProtKB: P0A0K8, P20831]
ChEMBL	Inhibition of wild-type Staphylococcus aureus DNA gyrase assessed as inhibition of supercoiling of pBR322 DNA after 60 min by gel electrophoresis assay	B	4.21	pIC50	62000	nM	IC50	J Med Chem (2011) 54: 3268-3282 [PMID:21425851]
ChEMBL	Inhibition of Staphylococcus aureus DNA gyrase by supercoiling assay	B	4.21	pIC50	62000	nM	IC50	J Med Chem (2011) 54: 3418-3425 [PMID:21443219]
ChEMBL	Inhibition of Staphylococcus aureus DNA gyrase by supercoiling assay	B	4.21	pIC50	62000	nM	IC50	J Med Chem (2007) 50: 199-210 [PMID:17228862]
ChEMBL	Inhibition of Staphylococcus aureus wild-type DNA gyrase supercoiling activity assessed as effect on conversion of relaxed pBR322 DNA to supercoiled form	B	4.21	pIC50	61700	nM	IC50	Antimicrob Agents Chemother (2007) 51: 2445-2453 [PMID:17502409]
ChEMBL	Inhibition of DNA supercoiling activity of Staphylococcus aureus DNA gyrase	B	4.5	pIC50	31500	nM	IC50	Antimicrob Agents Chemother (2010) 54: 3011-3014 [PMID:20404126]
ChEMBL	Inhibition of Staphylococcus aureus DNA gyrase supercoiling activity incubated for 25 min by ethidium bromide/bromophenol blue staining based agarose gel electrophoresis analysis	B	4.55	pIC50	28000	nM	IC50	ACS Med Chem Lett (2022) 13: 955-963 [PMID:35707162]
ChEMBL	Inhibition of Staphylococcus aureus Gyrase supercoiling activity assessed as reduction in supercoiling pBR322 DNA by measuring relaxation by bromophenol blue staining based TAE gel method	B	4.55	pIC50	28000	nM	IC50	J Med Chem (2021) 64: 15214-15249 [PMID:34614347]
ChEMBL	Inhibition of Staphylococcus aureus DNA gyrase using relaxed pBR322 DNA as substrate incubated for 45 mins by agarose gel electrophoresis method	B	4.58	pIC50	26430	nM	IC50	Eur J Med Chem (2020) 188: 111977-111977 [PMID:31927313]
ChEMBL	Inhibition of Staphylococcus aureus DNA gyrase using relaxed pBR322 as substrate by gel electrophoresis	B	4.88	pIC50	13200	nM	IC50	ACS Med Chem Lett (2020) 11: 2446-2454 [PMID:33335666]
ChEMBL	Inhibition of Staphylococcus aureus DNA gyrase supercoiling activity using pBR322 as substrate after 30 mins by agarose gel electrophoresis	B	5.32	pIC50	4800	nM	IC50	Bioorg Med Chem Lett (2018) 28: 2477-2480 [PMID:29871847]
ChEMBL	Inhibition of Staphylococcus aureus DNA gyrase supercoiling activity using pNO1 plasmid DNA as substrate incubated for 30 mins by fluorescence based microtiter plate reader assay	B	5.42	pIC50	3840	nM	IC50	Bioorg Med Chem Lett (2022) 57: 128499-128499 [PMID:34906671]
ChEMBL	Inhibition of Staphylococcus aureus DNA gyrase incubated for 30 mins in presence of relaxed plasmid DNA by supercoiling based gel electrophoresis analysis	B	5.94	pIC50	1150	nM	IC50	RSC Med Chem (2023) 14: 1114-1130 [PMID:37360390]
DNA gyrase subunit A in Escherichia coli (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1858] [GtoPdb: 3217] [UniProtKB: P0AES4]
ChEMBL	Inhibition of DNA supercoiling activity of Escherichia coli DNA gyrase gyrA G81C mutant	B	4.55	pIC50	28000	nM	IC50	Antimicrob Agents Chemother (2010) 54: 3011-3014 [PMID:20404126]
ChEMBL	Inhibition of His tagged Escherichia coli ATCC 25922 DNA gyrase A SD-LY mutant expressed in Escherichia coli BL21 (DE3) pLysS cells assessed as reduction in enzyme-mediated supercoiling of relaxed plasmid DNA pNO1 after 30 mins in presence of biotinylated TFO1 by fluorescence assay	B	5.59	pIC50	2600	nM	IC50	J Med Chem (2018) 61: 4456-4475 [PMID:29727185]
ChEMBL	Inhibition of DNA supercoiling activity of Escherichia coli DNA gyrase gyrA A67S mutant	B	6	pIC50	1000	nM	IC50	Antimicrob Agents Chemother (2010) 54: 3011-3014 [PMID:20404126]
ChEMBL	Inhibition of Escherichia coli ATCC 25922 DNA gyrase A assessed as reduction in enzyme-mediated supercoiling of relaxed pBR322 DNA by ethidium bromide staining based gel electrophoresis method	B	6	pIC50	1000	nM	IC50	J Med Chem (2019) 62: 7445-7472 [PMID:31276392]
DNA gyrase subunit A/DNA gyrase subunit B in Mycobacterium tuberculosis (target type: PROTEIN COMPLEX) [ChEMBL: CHEMBL3430898] [UniProtKB: P9WG45, P9WG47]
ChEMBL	Inhibition of Mycobacterium tuberculosis DNA gyrase supercoiling activity using relaxed pBR322 as substrate after 30 mins by agarose gel electrophoresis	B	4.42	pIC50	37725.5	nM	IC50	Bioorg Med Chem (2018) 26: 4551-4559 [PMID:30097361]
ChEMBL	Inhibition of Mycobacterium tuberculosis DNA gyrase assessed as reduction in supercoiling of relaxed pBR322 DNA substrate after 30 mins by ethidium bromide staining based agarose gel electrophoresis method	B	4.97	pIC50	10600	nM	IC50	Eur J Med Chem (2019) 161: 399-415 [PMID:30384044]
DNA gyrase subunit B in S.aureus (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1921666] [UniProtKB: P0A0K8]
ChEMBL	Inhibition of Staphylococcus aureus DNA gyrase subunit B ATPase activity using relaxed pNO1 plasmid as substrate incubated for 30 mins by microplate reader analysis	B	5.93	pIC50	1170	nM	IC50	RSC Med Chem (2023) 14: 2751-2767 [PMID:38107183]
DNA topoisomerase 4 subunit B in S.aureus (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2150841] [UniProtKB: P0C1S7]
ChEMBL	Inhibition of Staphylococcus aureus DNA topoisomerase 4 subunit B ATPase activity using relaxed pNO1 plasmid as substrate incubated for 30 mins by microplate reader analysis	B	4.62	pIC50	24110	nM	IC50	RSC Med Chem (2023) 14: 2751-2767 [PMID:38107183]
DNA topoisomerase II alpha in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1806] [GtoPdb: 2637] [UniProtKB: P11388]
ChEMBL	Inhibition of human topoisomerase 2 assessed as reduction in decatenation	B	4	pIC50	>100000	nM	IC50	Bioorg Med Chem Lett (2022) 65: 128648-128648 [PMID:35231579]
GABAA receptor π subunit/GABAA receptor β1 subunit/GABAA receptor δ subunit/GABAA receptor γ2 subunit/GABAA receptor α5 subunit/GABAA receptor α3 subunit/GABAA receptor γ1 subunit/GABAA receptor α2 subunit/GABAA receptor α4 subunit/GABAA receptor γ3 subunit/GABAA receptor α6 subunit/GABAA receptor α1 subunit/GABAA receptor β3 subunit/GABAA receptor β2 subunit/GABAA receptor ε subunit/GABA-A receptor; anion channel in Rat (target type: PROTEIN COMPLEX GROUP) [ChEMBL: CHEMBL1907607] [GtoPdb: 419, 410, 416, 414, 408, 406, 413, 405, 407, 415, 409, 404, 412, 411, 417] [UniProtKB: O09028, P15431, P18506, P18508, P19969, P20236, P23574, P23576, P28471, P28473, P30191, P62813, P63079, P63138, Q91ZM7, Q9ES14]
ChEMBL	Inhibition of [3H]muscimol binding to GABA A receptor with compound alone at 10 e-4 M	B	4	pIC50	100000	nM	IC50	J Med Chem (1993) 36: 1356-1363 [PMID:8388467]
ChEMBL	Inhibition of [3H]muscimol binding to GABA A receptor 4-biphenylacetic acid at 10 e-4 M	B	6.39	pIC50	410	nM	IC50	J Med Chem (1993) 36: 1356-1363 [PMID:8388467]
Kv11.1/HERG in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL240] [GtoPdb: 572] [UniProtKB: Q12809]
ChEMBL	Displacement of [3H]dofetilide from human ERG by fliter binding assay	B	4	pKi	>100000	nM	Ki	Bioorg Med Chem Lett (2007) 17: 2150-2155 [PMID:17303420]
ChEMBL	Inhibition of human ERG expressed in mammalian cells by patch clamp method	B	4.52	pIC50	>30000	nM	IC50	J Med Chem (2011) 54: 3418-3425 [PMID:21443219]
H3 receptor/Histamine H3 receptor in Rat (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4124] [GtoPdb: 264] [UniProtKB: Q9QYN8]
ChEMBL	Binding affinity to rat cerebral cortex histamine H3 receptor	B	9.18	pKi	0.65	nM	Ki	Bioorg Med Chem (2012) 20: 2889-2896 [PMID:22483590]
Human immunodeficiency virus type 1 integrase in Human immunodeficiency virus 1 (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3471] [UniProtKB: Q7ZJM1]
ChEMBL	Inhibition of recombinant HIV1 integrase strand transfer activity	B	4	pIC50	>100000	nM	IC50	J Med Chem (2006) 49: 1506-1508 [PMID:16509568]
Multidrug resistance protein mdtK in Escherichia coli (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1681613] [UniProtKB: P37340]
ChEMBL	Binding affinity to Escherichia coli K-12 multidrug efflux protein YdhE expressed in Escherichia coli AG100AX in presence of 0.02% DDM surfactant by fluorescence polarization assay	B	4.04	pKd	90900	nM	Kd	Antimicrob Agents Chemother (2008) 52: 3052-3060 [PMID:18591276]
Plasmodium berghei (target type: ORGANISM) [ChEMBL: CHEMBL612653]
ChEMBL	Antimalarial activity against liver stage Plasmodium berghei	F	7.22	pIC50	60	nM	IC50	Eur J Med Chem (2023) 256: 115458-115458 [PMID:37163950]
Plasmodium falciparum (target type: ORGANISM) [ChEMBL: CHEMBL364]
ChEMBL	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum IMT K2 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay	F	4.09	pIC50	80800	nM	IC50	J Med Chem (2009) 52: 7954-7957 [PMID:19908867]
ChEMBL	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum IMT10500 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay	F	4.13	pIC50	74800	nM	IC50	J Med Chem (2009) 52: 7954-7957 [PMID:19908867]
ChEMBL	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum FCR3 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay	F	4.13	pIC50	74300	nM	IC50	J Med Chem (2009) 52: 7954-7957 [PMID:19908867]
ChEMBL	Antimalarial activity against schizont stage of atovaquone-resistant Plasmodium falciparum Tm90C2b infected in erythrocytes assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs by scintillation counting analysis	F	4.14	pIC50	71800	nM	IC50	Medchemcomm (2011) 2: 430-435
ChEMBL	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum IMTVo1 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay	F	4.29	pIC50	51600	nM	IC50	J Med Chem (2009) 52: 7954-7957 [PMID:19908867]
ChEMBL	Antimalarial activity against schizont stage of chloroquine-susceptible Plasmodium falciparum 3D7 infected in erythrocytes assessed as inhibition of [3H]hypoxanthine incorporation after 48 hrs by scintillation counting analysis	F	4.33	pIC50	47000	nM	IC50	Medchemcomm (2011) 2: 430-435
ChEMBL	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay	F	4.34	pIC50	45900	nM	IC50	J Med Chem (2009) 52: 7954-7957 [PMID:19908867]
ChEMBL	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum FCM29 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay	F	4.34	pIC50	45600	nM	IC50	J Med Chem (2009) 52: 7954-7957 [PMID:19908867]
ChEMBL	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum PA infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay	F	4.34	pIC50	45500	nM	IC50	J Med Chem (2009) 52: 7954-7957 [PMID:19908867]
ChEMBL	Antimalarial activity against CQ-sensitive Plasmodium falciparum 3D7 infected in human erythrocytes after 48 hrs by SYBR Green1 dye based fluorescence assay	F	4.34	pIC50	45350	nM	IC50	ACS Med Chem Lett (2020) 11: 1450-1456 [PMID:32676153]
ChEMBL	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum IMTL1 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay	F	4.38	pIC50	41300	nM	IC50	J Med Chem (2009) 52: 7954-7957 [PMID:19908867]
ChEMBL	Antiplasmodial activity against asynchronous Plasmodium falciparum K1	F	4.42	pIC50	38000	nM	IC50	Eur J Med Chem (2018) 146: 1-14 [PMID:29360043]
ChEMBL	Antimalarial activity against CQ-resistant Plasmodium falciparum W2 infected in human erythrocytes after 48 hrs by SYBR Green1 dye based fluorescence assay	F	4.43	pIC50	37080	nM	IC50	ACS Med Chem Lett (2020) 11: 1450-1456 [PMID:32676153]
ChEMBL	Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 infected in human erythrocytes assessed as parasite growth inhibition after 50 hrs by SYBR Green1 dye-based fluorescence assay	F	4.47	pIC50	33900	nM	IC50	Eur J Med Chem (2014) 77: 280-287 [PMID:24650715]
ChEMBL	Antiplasmodial activity against synchronized Plasmodium falciparum K1	F	4.49	pIC50	32000	nM	IC50	Eur J Med Chem (2018) 146: 1-14 [PMID:29360043]
ChEMBL	Antiplasmodial activity against synchronized Plasmodium falciparum 3D7	F	4.51	pIC50	31000	nM	IC50	Eur J Med Chem (2018) 146: 1-14 [PMID:29360043]
ChEMBL	Antiplasmodial activity against asynchronous Plasmodium falciparum 3D7	F	4.51	pIC50	31000	nM	IC50	Eur J Med Chem (2018) 146: 1-14 [PMID:29360043]
ChEMBL	Antimalarial activity against CQ-sensitive Plasmodium falciparum 3D7 infected in human erythrocytes after 96 hrs by SYBR Green1 dye based fluorescence assay	F	4.58	pIC50	26260	nM	IC50	ACS Med Chem Lett (2020) 11: 1450-1456 [PMID:32676153]
ChEMBL	Antimalarial activity as 2nd generation ring-stage chloroquine-resistant Plasmodium falciparum W2 after 48 hrs by flow cytometry	F	4.6	pIC50	24900	nM	IC50	Antimicrob Agents Chemother (2007) 51: 3485-3490 [PMID:17698630]
ChEMBL	Antiplasmodial activity against asynchronous Plasmodium falciparum CS2	F	4.62	pIC50	24000	nM	IC50	Eur J Med Chem (2018) 146: 1-14 [PMID:29360043]
ChEMBL	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human erythrocytes assessed as parasite growth inhibition after 50 hrs by SYBR Green1 dye-based fluorescence assay	F	4.64	pIC50	23100	nM	IC50	Eur J Med Chem (2014) 77: 280-287 [PMID:24650715]
ChEMBL	Antimalarial activity against CQ-resistant Plasmodium falciparum W2 infected in human erythrocytes after 96 hrs by SYBR Green1 dye based fluorescence assay	F	4.64	pIC50	22850	nM	IC50	ACS Med Chem Lett (2020) 11: 1450-1456 [PMID:32676153]
ChEMBL	Antiplasmodial activity against synchronized Plasmodium falciparum CS2	F	4.7	pIC50	20000	nM	IC50	Eur J Med Chem (2018) 146: 1-14 [PMID:29360043]
ChEMBL	Antimalarial activity against blood stage form of Plasmodium falciparum assessed as incorporation of [3H]hypoxanthine after 72 hrs by liquid scintillation counting	F	4.7	pIC50	20000	nM	IC50	Eur J Med Chem (2014) 77: 280-287 [PMID:24650715]
ChEMBL	Antimalarial activity against schizont stage of chloroquine-resistant Plasmodium falciparum W2 infected in erythrocytes assessed as inhibition of [3H]hypoxanthine incorporation after 96 hrs by scintillation counting analysis	F	4.77	pIC50	16800	nM	IC50	Medchemcomm (2011) 2: 430-435
ChEMBL	Antimalarial activity against schizont stage of atovaquone-resistant Plasmodium falciparum Tm90C2b infected in erythrocytes assessed as inhibition of [3H]hypoxanthine incorporation after 96 hrs by scintillation counting analysis	F	4.82	pIC50	15300	nM	IC50	Medchemcomm (2011) 2: 430-435
ChEMBL	Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in erythrocytes after 96 hrs by [3H]hypoxanthine incorporation assay	F	4.85	pIC50	14100	nM	IC50	J Med Chem (2009) 52: 7954-7957 [PMID:19908867]
ChEMBL	DNDI: Malaria in Vitro, 72 hour	F	4.88	pIC50	13190	nM	IC50	Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning
ChEMBL	Antimalarial activity against schizont stage of chloroquine-susceptible Plasmodium falciparum 3D7 infected in erythrocytes assessed as inhibition of [3H]hypoxanthine incorporation after 96 hrs by scintillation counting analysis	F	4.89	pIC50	12800	nM	IC50	Medchemcomm (2011) 2: 430-435
ChEMBL	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in erythrocytes after 96 hrs by [3H]hypoxanthine incorporation assay	F	5	pIC50	10100	nM	IC50	J Med Chem (2009) 52: 7954-7957 [PMID:19908867]
ChEMBL	Antimalarial activity as 2nd generation ring-stage chloroquine-sensitive Plasmodium falciparum 3D7 after 48 hrs by flow cytometry	F	5.03	pIC50	9440	nM	IC50	Antimicrob Agents Chemother (2007) 51: 3485-3490 [PMID:17698630]
ChEMBL	Antimalarial activity as 3rd generation ring-stage chloroquine-sensitive Plasmodium falciparum 3D7 after 48 hrs dose then 48 hrs drug-free	F	5.52	pIC50	3040	nM	IC50	Antimicrob Agents Chemother (2007) 51: 3485-3490 [PMID:17698630]
ChEMBL	Antimalarial activity as 3rd generation ring-stage chloroquine-resistant Plasmodium falciparum W2 after 48 hrs dose then 48 hrs drug-free	F	5.76	pIC50	1750	nM	IC50	Antimicrob Agents Chemother (2007) 51: 3485-3490 [PMID:17698630]
ChEMBL	Antimalarial activity against chloroquine-resistant Plasmodium falciparum RKL-9 schizont infected in RBC measured after 24 to 30 hrs hrs by giemsa staining based light microscopic method	F	6.4	pIC50	401	nM	IC50	Bioorg Med Chem (2017) 25: 1949-1962 [PMID:28237557]
ChEMBL	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum MRC-2 schizont infected in RBC measured after 24 to 30 hrs hrs by giemsa staining based light microscopic method	F	7.3	pIC50	50	nM	IC50	Bioorg Med Chem (2017) 25: 1949-1962 [PMID:28237557]
Topoisomerase IV in S.aureus (target type: PROTEIN COMPLEX) [ChEMBL: CHEMBL3038508] [UniProtKB: P0C1S7, P0C1U9]
ChEMBL	Inhibition of Staphylococcus aureus DNA topoisomerase 4 using supercoiled plasmid DNA as substrate	B	4.59	pIC50	25420	nM	IC50	RSC Med Chem (2023) 14: 1114-1130 [PMID:37360390]
ChEMBL	Inhibition of Staphylococcus aureus topoisomerase 4 using pNO1 plasmid DNA as substrate incubated for 30 mins by fluorescence based microtiter plate reader assay	B	5.04	pIC50	9160	nM	IC50	Bioorg Med Chem Lett (2022) 57: 128499-128499 [PMID:34906671]
ChEMBL	Inhibition of Staphylococcus aureus topoisomerase IV decatenation activity using kDNA as substrate by ethidium bromide/bromophenol blue staining based agarose gel electrophoresis analysis	B	5.07	pIC50	8600	nM	IC50	J Med Chem (2021) 64: 15214-15249 [PMID:34614347]
ChEMBL	Inhibition of Staphylococcus aureus DNA topoisomerase 4 decatenation activity using kDNA as substrate incubated for 10 to 20 min by ethidium bromide/bromophenol blue staining based agarose gel electrophoresis analysis	B	5.07	pIC50	8600	nM	IC50	ACS Med Chem Lett (2022) 13: 955-963 [PMID:35707162]
ChEMBL	Inhibition of wild type Staphylococcus aureus ATCC 29213 topoisomerase-4 subunit 2GrlA/2GrlB assessed as pBR322 relaxation after 1 hr	B	5.1	pIC50	8000	nM	IC50	J Med Chem (2013) 56: 7396-7415 [PMID:23968485]
ChEMBL	Inhibition of Staphylococcus aureus topoisomerase-4 assessed as reduction in decatenation of kinetoplast DNA agarose gel electrophoresis method	B	5.4	pIC50	4000	nM	IC50	ACS Med Chem Lett (2020) 11: 2446-2454 [PMID:33335666]
ChEMBL	Inhibition of Staphylococcus aureus topoisomerase 4 assessed as reduction in decatenation using kDNA as substrate incubated for 30 mins by fluorimetric assay	B	6.26	pIC50	550	nM	IC50	Eur J Med Chem (2022) 228: 114021-114021 [PMID:34871841]
Topoisomerase IV subunit A in S.aureus (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4088] [UniProtKB: P0C1U9]
ChEMBL	Inhibition of Staphylococcus aureus ATCC 29213 DNA topoisomerase 4 subunit ParC assessed as reduction in decatenation of kinetoplast DNA incubated for 30 mins by ethidium bromide staining based gel electrophoresis method	B	4.89	pIC50	13000	nM	IC50	J Med Chem (2019) 62: 7445-7472 [PMID:31276392]
ChEMBL	Inhibition of topoisomerase 4 decatenation in Staphylococcus aureus ATCC 29213	B	5.64	pIC50	2300	nM	IC50	J Med Chem (2006) 49: 39-42 [PMID:16392790]
ChEMBL	Inhibitory activity against Staphylococcus aureus ATCC 29213 wild type Topo 4	B	6	pIC50	1000	nM	IC50	Bioorg Med Chem Lett (2006) 16: 1277-1281 [PMID:16337789]
ChEMBL	Inhibitory activity against wild type Staphylococcus aureus topoisomerase 4	B	6	pIC50	1000	nM	IC50	Bioorg Med Chem Lett (2006) 16: 1272-1276 [PMID:16337791]
DNA topoisomerase 4 subunit A/Topoisomerase IV subunit A in Escherichia coli (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1895] [GtoPdb: 3225] [UniProtKB: P0AFI2]
ChEMBL	Inhibition of Escherichia coli ATCC 25922 DNA topoisomerase 4 subunit ParC assessed as reduction in decatenation of kinetoplast DNA incubated for 30 mins by ethidium bromide staining based gel electrophoresis method	B	4.29	pIC50	51000	nM	IC50	J Med Chem (2019) 62: 7445-7472 [PMID:31276392]

ChEMBL data shown on this page come from version 34:

Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]